The global brain tumor diagnosis and therapeutics market size is expected to reach USD 4.94 billion by 2030, registering a CAGR of 7.1% during the forecast period, according to a new report by Grand View Research, Inc. The market is expected to pose lucrative growth over the forecast period, owing to the increasing incidence of various brain cancers, particularly glioblastoma, coupled with the rising geriatric population.
Increasing Public-Private Partnerships (PPPs) in the health sector, which are modernizing diagnostic imaging and radiology services, are supporting the expansion of this industry. Emerging technologies like Sodium Magnetic Resonance Imaging(23Na MRI), Positron Emission Tomography (PET), and Chemical Exchange Saturation Transfer (CEST) are used to detect the response of brain tumors in multicenter clinical trial settings. In addition, these technologies are helpful in quantitatively imaging tumor response to therapies, thereby promoting their use during treatment.
These technologies have the potential to extend MRI beyond anatomical imaging by providing information on physiology and cellular metabolism, thereby increasing the efficiency of diagnosis. Hence, the market is expected to witness productive growth over the forecast period.
Moreover, ongoing research in molecular diagnostics to understand cell biology at the cellular level of malignancy and identification of gene mutations associated with malignancy is anticipated to significantly contribute toward the growth of the industry.
On the other hand, the high cost of diagnosing brain tumors, which ranges from USD 450 to 12,200, is likely to hinder the growth of the global brain tumor diagnosis market.
Request a free sample copy or view report summary: Brain Tumor Diagnosis And Therapeutics Market Report
CT scan segment dominated the market with a revenue share of 25.6% in 2023 and is also likely to grow at a significant rate during the forecast period
Targeted therapy segment drives market growth through its improved efficiency, reduced side effects, resistance mitigation capabilities, and advances in molecular profiling techniques, and expected to register a CAGR of 7.7% in the forecast period.
North America is expected to dominate the brain tumor diagnosis and therapeutics market, owing to developed healthcare infrastructure coupled with rising awareness regarding advanced technologies amongst the population in this region. In addition, increasing consumer disposable income supported by healthcare insurance and reimbursement policies in the U.S. is expected to spur growth.
Grand View Research has segmented the global brain tumor diagnosis and therapeutics market report based on type, product, diagnosis, therapeutics, end-use, and region:
Brain Tumor Diagnosis And Therapeutics Type Outlook (Revenue, USD Million, 2018 - 2030)
Primary
Meningioma
Gliomas
Astrocytomas
Pituitary Tumors
Others
Secondary
Brain Tumor Diagnosis And Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)
Stains & Varnishes
Shellacs
Lacquers
Others
Brain Tumor Diagnosis And Therapeutics Diagnosis Outlook (Revenue, USD Million, 2018 - 2030)
MRI
CT-Scan
Tissue Sampling
PET-CT Scan
Cerebral Arteriogram
Lumbar Puncture
Molecular Testing
EEG
Others
Brain Tumor Diagnosis And Therapeutics Therapeutics Outlook (Revenue, USD Million, 2018 - 2030)
Surgery
Radiation Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Others
Brain Tumor Diagnosis And Therapeutics End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Oncology Treatment Centers
Others
Brain Tumor Diagnosis And Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Brain Tumor Diagnosis And Therapeutics Market
Amgen Inc.
AstraZeneca
Bayer AG
GE HealthCare
F. Hoffmann-La Roche Ltd
Eisai Co., Ltd
Bristol-Myers Squibb Company
Pfizer Inc.
Shimadzu Corporation
Siemens Healthineers AG
"The quality of research they have done for us has been excellent..."